Mesoblast shares fall on trial's mixed results with heart injection treatment - Stockhead
Mesoblast shares have dropped more than 12 per cent after a six-year trial of its stem cell treatment remestemcel-L failed to meet primary endpoints.
Mesoblast shares fall on trial's mixed results with heart injection treatment - Stockhead
Mesoblast shares have dropped more than 12 per cent after a six-year trial of its stem cell treatment remestemcel-L failed to meet primary endpoints.